Meddelelse nr. 08/2024: Forløb af ordinær generalforsamling
Strategic Investments A/S (CVR nr. 71064719) afholdte fredag d. 26. april 2024 kl. 10:00 ordinær generalforsamling. Indkaldelse, dagsorden og de fuldstændige forslag fremgår af selskabsmeddelelse nr. 06/2024 af d. 4. april 2024.
Bestyrelsen havde udpeget advokat Jens Ahrendt, Mazanti-Andersen Advokatpartnerselskab som dirigent. Dirigenten konstaterede, at generalforsamlingen var rettidigt varslet og beslutningsdygtig.
Dagsordenspunkt 1-3
Adm. dir. Jens Black gennemgik årets væsentligste begivenheder, redegjorde for selskabets resultatudvikling i 2023 og gennemgik selskabets balance.
Forud for generalforsamlingen havde selskabet offentliggjort delårsrapport for 1. kvartal 2024. Jens Black opsummerede kort udviklingen i 1. kvartal 2024 herunder kvartalets resultat og afkast i hovedtal.
Med henvisning til årsrapporten indstillede bestyrelsen til generalforsamlingen, at der, i lighed med for 2022, udloddes udbytte for regnskabsåret 2023 på DKK 0,02 pr. aktie.
Beretningen blev taget til efterretning. Årsrapport og resultatdisponering blev godkendt.
Dagsordenspunkt 4, Bemyndigelse til bestyrelsen til køb af selskabets egne aktier
Generalforsamlingen forlængede den gældende bemyndigelse til opkøb af indtil 10% af aktiekapitalen. Bemyndigelsen løber frem til d. 26. april 2029.
Dagsordenspunkt 5, Valg af bestyrelse
Lars Stoltze, Peter Ott og Katja Nowak Nielsen blev genvalgt.
Efter generalforsamlingen konstituerede bestyrelsen sig uændret med Peter Ott som formand.
Dagsordenspunkt 6, Valg af revisor
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (cvr. 33 77 12 31) blev valgt.
Dagsordenspunkt 7a, Forslag om ændring af selskabets vedtægter
Ændringerne havde baggrund i et ønske om nærmere at afspejle selskabets forpligtelser i henhold til lov om forvaltere af alternative investeringsfonde.
Forslaget blev vedtaget.
Dagsordenspunkt 7b, Forslag om bestyrelseshonorarer for 2024
Basishonoraret for menige medlemmer for 2024 blev fastsat til DKK 135.000 pr. medlem. Formanden for bestyrelsen honoreres med det dobbelte af basishonoraret.
Dagsordenspunkt 7c, Forslag om bemyndigelse til konvertible gældsbreve
Bestyrelsen blev bemyndiget til at optaget lån ved udstedelse af konvertible gældsbreve med et lånebeløb på op til DKK 150m uden fortegningsret for selskabets eksisterende kapitalejere samt foretage de dertil hørende kapitalforhøjelser.
Der var ikke yderligere emner til behandling.
Generalforsamlingen bemyndigede enstemmigt og med samtlige stemmer advokat Jens Ahrendt, med substitutionsret, til at anmelde det vedtagne til Erhvervsstyrelsen og til i forbindelse hermed at foretage sådanne ændringer og tilføjelser i det vedtagne, i vedtægterne og i øvrige forhold, som Erhvervsstyrelsen måtte kræve for at registrere det på generalforsamlingen vedtagne.
Bilagt dette referat er kopi af de slides der blev anvendt til præsentation under de enkelte dagsordenspunkter.
Således passeret.
Med venlig hilsen
Strategic Investments A/S
Bestyrelsen
Yderligere oplysninger:
Jens Black, adm. direktør, telefon +45 30 65 41 74
Bilag:
Slides fra ordinær generalforsamling d. 26. april 2024
Vedhæftede filer
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Inteleos to Host Roundtable on Advancing Maternal Health through Point-Of-Care-Ultrasound Certification6.5.2024 23:25:48 CEST | Press release
Global healthcare certification leader convenes experts to discuss ultrasound training and certification as key strategy to reduce maternal mortality ROCKVILLE, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, will host a roundtable discussion titled "Advancing Maternal and Fetal Health through POCUS Training and Certification" on May 29 alongside a side event during the WHO World Health Assembly and the AI for Good Global Summit. The roundtable will explore the urgent need to expand point-of-care ultrasound (POCUS) training and certification for frontline maternal health clinicians as a crucial intervention for reducing preventable maternal deaths and achieving UN Sustainable Development Goals, and how to implement to scale. Despite the increased availability of affordable ultrasound technology, there remains a significant training gap that limits access to this diagnostic tool, especially in low-resource areas with high matern
ETC’s Commercial/Industrial Units Awarded Three Contracts Totaling $15.9 Million6.5.2024 22:15:00 CEST | Press release
SOUTHAMPTON, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation’s (OTC Pink: ETCC) (“ETC” or the “Company”) Sterilization Systems Group announced it has been awarded $13.9 million in contracts from two multi-national medical device manufacturers. The contracts include four, sixteen pallet ethylene oxide (“EO”) sterilization system chambers with related conveyer systems, and a large capacity vacuum drying chamber with preconditioning. “These contracts reflect ETC Sterilization Systems Group’s dedication to innovation in our mechanical designs, control systems and software expertise to meet the challenging requirements of this market,” states Eric Hunnicutt, ETC Director of EO Sterilizer Sales. ETC’s Sterilization Systems Group offers Steam and Ethylene Oxide (“EO”) Sterilizer Systems, Vacuum Dryers, Software Systems, and project management services to the Medical Device, Pharmaceutical, Biotechnology, and Life Science industries. ETC’s systems are specially design
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC6.5.2024 22:05:00 CEST | Press release
If approved, Zeno will be the first targeted therapy for NRG1+ cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) non-small cell lung (NSCLC) and NRG1+ pancreatic (PDAC) cancer. “FDA acceptance of our first BLA represents an important achievement for Merus and an important potential treatment opportunity for patients with NRG1+ cancer, a disease with poor prognosis and high unmet need,” said Dr. Andrew Joe, Chief Medical Officer at Merus. “Zenocutuzumab has the potential to be the first and only targeted therapy for patients with NRG1+ lung and
Nokia Corporation: Repurchase of own shares on 06.05.20246.5.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 06 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 06.05.2024 Espoo, Finland – On 06 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL385,6823.45CEUX--BATE--AQEU--TQEX--Total385,6823.45 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra
Trading in Novo Nordisk shares by board members, executives and associated persons6.5.2024 21:02:16 CEST | Press release
Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Novo Holdings A/S, associated to Kasim Kutay 2 Reason for the notification a) Position/status Member of the Board of Directors b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A&S b) LEI 549300DAQ1CVT6CXN342